Summit and MD Anderson Partner to Advance Ivonescimab

Summit Therapeutics and The University of Texas MD Anderson Cancer Centre have announced a strategic five-year partnership agreement to expedite the development of ivonescimab. The partnership combines Summit's experimental PD-1/VEGF bispecific antibody with MD Anderson's clinical infrastructure and research experience to identify new development opportunities, including tumors not currently included in the drug's current development plan. MD Anderson will spearhead clinical trials across various tumor types to assess the safety and clinical value of ivonescimab, and may also find biomarkers through supplementary research.

Early research may focus on glioblastoma, colorectal, skin, breast, and renal cell carcinoma cancers, increasing the scope and depth of the development program. MD Anderson and Summit will collaborate on the design and conduct of preclinical and clinical studies with oversight from a joint steering committee, with research expected to begin later this year. The collaboration aims to bring the innovative advancement on immunotherapy and anti-angiogenic standards to as many patients as possible and accelerate the growing clinical development efforts for ivonescimab.